<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5000">
  <stage>Registered</stage>
  <submitdate>2/04/2015</submitdate>
  <approvaldate>2/04/2015</approvaldate>
  <nctid>NCT02419417</nctid>
  <trial_identification>
    <studytitle>Study of BMS-986158 in Subjects With Select Advanced Solid Tumors</studytitle>
    <scientifictitle>A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym>BET</trialacronym>
    <secondaryid>2015-000324-29</secondaryid>
    <secondaryid>CA011-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Indications Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986158

Experimental: Part 1 A (Dose Escalation): Treatment Arm A - Subjects will be treated at increasing doses of BMS-986158 until the maximum tolerated dose is reached.

Experimental: Part 1A (Dose Escalation): Treatment Arm B - Subjects will be treated at increasing doses of BMS-986158 until the maximum tolerated dose is reached.

Experimental: Part 1A (Dose Escalation): Treatment Arm C - Subjects will be treated at increasing doses of BMS-986158 until the maximum tolerated dose is reached.

Experimental: Part 2A (Dose Expansion): Treatment Arm A - Subjects will be treated at maximum tolerated dose.

Experimental: Part 2A (Dose Expansion): Treatment Arm B - Subjects will be treated at maximum tolerated dose.

Experimental: Part 2A (Dose Expansion): Treatment Arm C - Subjects will be treated at maximum tolerated dose.


Treatment: drugs: BMS-986158


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs) - Safety as measured by the rate of incidence of adverse events (AEs) at its worst grade, serious adverse events (SAEs) at its worst grade, adverse events leading to discontinuations, deaths, frequency of laboratory test toxicity grade shifting from baseline</outcome>
      <timepoint>Safety will be evaluated from the time that the subject signs the informed consent, and for 30 days after the last dose of study drug or until AEs have returned to = grade 1 or baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Best Overall Response</outcome>
      <timepoint>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR)</outcome>
      <timepoint>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response</outcome>
      <timepoint>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival Rate (PFSR) at week 't'</outcome>
      <timepoint>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed plasma concentration (Tmax) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent terminal phase half-life (T-HALF) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent total body clearance, reported only for parent, not for metabolite (CLT/F) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F) for single dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed plasma concentration (Tmax) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The minimum observed concentration within a dosing interval (Cmin) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Concentration at the end of a dosing interval (Ctau) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg]) (DF) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>[Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Accumulation Index (AI) for multiple dose of BMS-986158 - Ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff) for multiple dose of BMS-986158</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T))</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF))</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU))</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Summary Changes in Expression of BET regulated Genes in Blood</outcome>
      <timepoint>Cycle 1 Day 1 through Cycle 2 Day 15 dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in QTcF</outcome>
      <timepoint>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        

          -  Must have triple negative breast cancer, ovarian (Serous histology for expansion
             phase), small cell lung cancer, or other solid tumors

          -  Expected to have life expectancy of at least 3 months

          -  Men and women 18 years old or older

          -  At least one measurable lesion at baseline by CT or MRI as per response evaluation
             criteria in solid tumors (RECIST) v1.1

          -  Eastern Cooperative Oncology Group (ECOG) of 0 to 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Serious or uncontrolled medical disorders

          -  Concomitant second malignancies

          -  Uncontrolled or significant cardiovascular disease

          -  Inadequate bone marrow function

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>5/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Local Institution - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastrict</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle Upon Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of BMS-986158 in subjects with select advanced solid tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02419417</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</name>
      <address />
      <phone />
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>